Bevacizumab Biosimilar Mixture from Mexico
Bulk mixed immunological product with bevacizumab monoclonal antibodies targeting VEGF for colorectal cancer therapy. Classified in HTS 3002.14.0010 as a mixed monoclonal immunological product not in retail form. Contains antibody, surfactants, and buffers.
Duty Rate — Mexico → United States
100%
Rate breakdown
9903.04.60100%Pharmaceuticals: patented pharma articles — 100% floor rate
9903.05.860%Universal product exemption (U.S. note 52(b))
9903.05.900%Articles already subject to Section 232 (steel/aluminum/copper + derivatives, autos + parts, wood, medium/heavy vehicles + parts, semiconductors, patented pharma) — U.S. note 52(f)
Import Tips
• Submit comparability protocols for biosimilars to FDA prior to import
• Ensure sterile filtration certification; test for endotoxins in bulk solutions
• Document mixture ratio to avoid disputes over 'unmixed' vs 'mixed' status